Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from pharmaphorum

08:46 EST 18th December 2018 | BioPortfolio

Here are the most relevant search results for "pharmaphorum" found in our extensive news archives from over 250 global news sources.

More Information about pharmaphorum on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about pharmaphorum for you to read. Along with our medical data and news we also list pharmaphorum Clinical Trials, which are updated daily. BioPortfolio also has a large database of pharmaphorum Companies for you to search.

Showing News Articles 1–25 of 798 from pharmaphorum

Tuesday 18th December 2018

BMS looks to RNA splicing to boost immunotherapies

Bristol-Myers Squibb’s quest to claim dominance in the immunotherapy space continues through a new collaboration with Eisai and its US-based precision medicine subsidiary H3 Biomedicine to evaluate whether drugs leveraging H3’s RNA splicing platform ...

Alkermes/Biogen hope for less tummy trouble with new MS pill

Alkermes and Biogen have filed a new multiple sclerosis pill with the FDA, which they hope will treat the disease with fewer unpleasant gastrointestinal side effects than the big pharma’s older MS drug, Tecfidera. While Tecfidera (dimethyl fumarat...

Merck bags adjuvant okay for Keytruda in melanoma

Checkpoint inhibitors have already revolutionised the treatment of advanced melanoma, and Merck & Co has just claimed approval for even earlier use of its Keytruda product in Europe. The European Medicines Agency has approved PD-1 inhibitor Ke...

Monday 17th December 2018

Celltrion/Teva's Herceptin biosimilar approved in US

The FDA has approved Celltrion and Teva’s biosimilar of Roche’s breast cancer drug Herceptin, the second potential competitor to the cancer blockbuster in the US. Herceptin is due to go off patent in the US next year, and Mylan and Biocon already ...

Merck to buy animal health firm Antelliq for $2.4bn

Merck & Co is to buy animal health firm Antelliq Group for $2.4 billion in a bid to bolster this fast-growing business unit. Antelliq, which is majority owned by private investors BC Partners, makes digital identification products for livestoc...

ConvaTec looks to support UK wound care through sector deal

Wound care specialist ConvaTec has welcomed the UK government's Sector Deal for wound care and set out how it plans to support the country’s industry going forward. The new sector deal was announced last week. Through collaboration between the Aca...

Brexit affecting supplies of generic drugs, say pharmacists

Brexit is already affecting supply and prices of drugs in UK pharmacies, the BBC has reported. The BBC’s 5 Live Breakfast reported that pharmacies are stockpiling generic drugs, and prices are fluctuating amid the political uncertainty. Manufac...

J&J hits back over asbestos in talc claims

Shares in Johnson & Johnson slid around 10% on Friday after a Reuters article claimed the company had known for decades about asbestos in talcum powder products. In a rebuttal, J&J says that the Reuters’ article is “one-sided, false, and i...

Friday 14th December 2018

Lilly focuses on tau with AC Immune Alzheimer's R&D tie-up

Eli Lilly has paid $81m to develop drugs targeting aggregation of tau proteins associated with Alzheimer’s with Swiss biotech AC Immune, as focus shifts away from therapies targeting clumps of amyloid proteins found in the brains of patients with the...

Astellas gains three cancer drugs with $405m Potenza buy

Astellas has taken an option to acquire US biotech Potenza Therapeutics after the companies spent more than three years working together on cancer immunotherapies. The Japanese pharma said the acquisition marks the successful outcome of a collabor...

CarThera raises €9m to tackle the blood-brain barrier

French company CarThera has raised €9 million in its Series B funding round to help it develop ultrasound-based medical devices to treat brain disorders and overcome the challenges of the blood-brain barrier. The funding, equivalent to $10.3 milli...

Ipsen warns over medicine supplies amid Brexit uncertainty

France’s Ipsen has become the latest pharma company to warn about the impact of Brexit on the pharma industry and patients’ access to medicines. As Theresa May attempts to drum up support for her Brexit deal, the French pharma said it was taking s...

WuXi AppTec eyes acquisitions after $1bn Hong Kong IPO

Chinese biotech WuXi AppTec has completed its listing on Hong Kong’s HKEX, raising $967m just months after making its debut on the Shanghai exchange. The company – which provides contract research, development and manufacturing services to pharma,...

Thursday 13th December 2018

NICE rejects Alnylam and Akcea's amyloidosis drugs

NICE has rejected two pioneering drugs for the rare inherited condition, hereditary transthyretin-related amyloidosis (hATTR) in first draft guidance. The cost-effectiveness body had been using an assessment system for highly specialised technolog...

J&J's Tremfya outperforms Novartis' Cosentyx in psoriasis

A large head-to-head study has shown Johnson & Johnson’s psoriasis drug Tremfya outperformed Novartis’ rival, Cosentyx, which had previously set standards in moderate to severe disease. Results from the late-stage study in moderate to severe p...

AZ begins liver cancer immunotherapy tie-up with AVEO

AstraZeneca has announced a collaboration with US biotech AVEO oncology to investigate a potential cancer immunotherapy combination in liver cancer. AZ’s Imfinzi (durvalumab) immunotherapy has suffered a series of setbacks but the Anglo-Swedish ph...

Garmin to develop wearables for clinical trials with ActiGraph

Tech-giant Garmin is stepping into the medical wearables space through a new collaboration with ActiGraph. The partnership will explore health and activity monitoring innovations combining Garmin wearables with ActiGraph‘s CentrePoint data analyti...

Neurocrine slumps as Tourette's drug fails clinical trial

Shares in Neurocrine Biosciences slumped by as much as a fifth after a much-anticipated trial in Tourette’s syndrome missed the mark. The phase IIb T-Force GOLD study of valbenazine showed that the VMAT2 inhibitor – already sold under the trade na...

Wednesday 12th December 2018

Novo begins R&D tie-up with AI biotech e-Therapeutics

Novo Nordisk has signed a deal with UK biotech e-Therapeutics to use its AI-based drug discovery technology to find new therapies for type 2 diabetes. e-Therapeutics will work with Novo for a year and use its technology to identify novel intervent...

Axovant axes neuroscience drug, focuses on gene therapies

Swiss biotech Axovant started the year badly, dropping its Alzheimer’s drug intepirdine after it failed in a trial, and it has ended with another flop from a neuroscience drug, nelotanserin. Axovant is from the Roivant family of companies led by C...

Shinichi Tamura re-takes CEO role at Sosei

Sosei has announced that its founder and former CEO Shinichi Tamura will be re-taking the position of CEO as of next year. Current President & CEO Peter Bains will step down on 31 December 2018. He will also resign as a director of the Company...

Eisai, Takeda and GARDP hunt for new antibiotics

The not-for-profit Global Antibiotic Research and Development Partnership has joined forces with Eisai and Takeda to search for new antibiotics. Under a new agreement the Japanese pharma companies will access and screen molecules from Eisai and Ta...

FDA clears Pear/Sandoz app for opioid use disorder

A second mobile app developed by Pear Therapeutics to help opioid use disorder patients who have a more successful response to therapy has been given a green light by the FDA. The app – reSET-O – is billed as a “digital therapeutic” that can be pr...

Clark Health Communications forms alliance with Egg

London-based consultancy Clark Health Communications is partnering with digital solutions agency Egg in a collaboration that will see them offer their services to each other’s clients. The move could combine Clark Health Communications' medical co...

Tuesday 11th December 2018

NICE reveals new standards for digital tech

NICE has published new standards setting out the requirements needed to develop digital health technologies for the NHS and speed up uptake of products like healthcare apps and wearable devices. Working collaboratively NHS England, NICE, NHS Digit...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks